Compare Raymond James Financial, Inc. (RJF) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raymond James Financial, Inc. vs TransMedics Group Inc — how do they compare? Raymond James Financial, Inc. trades at $167 (market cap $32.73B), while TransMedics Group Inc trades at $71.34 (market cap $2.57B). The key difference: Raymond James Financial, Inc. is far larger — about 12.7× TransMedics Group Inc's market cap, and Raymond James Financial, Inc. pays a 1.29% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| RJF | TMDX | |
|---|---|---|
Market Cap | $32.73B | $2.57B |
Sector | Financials | Technology |
52-Week High | $176.43 | $150.42 |
52-Week Low | $140.89 | $61.99 |
Dividend Yield | 1.29% | — |
Enterprise Value | — | $2.97B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
